

Supplementary Table 1. Body weight, hemodynamic parameters, liver biochemistry, and arterial gas analysis of sham and CBDL rats receiving rosuvastatin or vehicle treatment

	Sham rats		CBDL rats	
	Rosuvastatin	Control	Rosuvastatin	Control
	(n=11)	(n=10)	(n=11)	(n=10)
BW prior (g)	264 ± 20	279 ± 70	260 ± 16	269 ± 12
BW post (g)	413 ± 24	410 ± 23	337 ± 27 <sup>a,*</sup>	371 ± 27
MAP (mmHg)	128 ± 13	122 ± 14	109 ± 14 <sup>*</sup>	110 ± 14 <sup>*</sup>
PP (mmHg)	6.7 ± 2.3	7.5 ± 1.1	15.9 ± 2.5 <sup>*</sup>	15.9 ± 2.4 <sup>*</sup>
HR (beats/min)	398 ± 52	394 ± 56	353 ± 45	369 ± 53
ALT (IU/L)	74 ± 22	76 ± 21	201 ± 164 <sup>*</sup>	234 ± 95 <sup>*</sup>
AST (IU/L)	296 ± 123	320 ± 100	1362 ± 1162 <sup>*</sup>	1262 ± 340 <sup>*</sup>
TB (mg/dL)	0.09 ± 0.01	0.08 ± 0.01	7.96 ± 1.22 <sup>*</sup>	8.21 ± 1.58 <sup>*</sup>
PaO <sub>2</sub> (mmHg)	89.5 ± 4.1	91.9 ± 4.9	90.7 ± 4.3 <sup>#</sup>	85.4 ± 5.6 <sup>b</sup>
PaCO <sub>2</sub> (mmHg)	39.7 ± 4.0	39.1 ± 2.7	37.3 ± 3.2	36.9 ± 3.5
AaPO <sub>2</sub> (mmHg)	10.9 ± 4.1	9.3 ± 2.4	12.6 ± 2.2 <sup>a</sup>	18.5 ± 4.2 <sup>*</sup>
VEGF (pg/ml)	NA	NA	17.0 ± 2.9 <sup>a</sup>	20.7 ± 4.9
TNF-α(pg/ml)	NA	NA	20.1 ± 4.4 <sup>a</sup>	24.9 ± 3.7

BW prior: body weight before CBDL or sham operation; BW post: body weight after different treatments; MAP: mean arterial pressure; PP: portal pressure; HR: heart rate; AST: aspartate aminotransferase, ALT: alanine aminotransferase, TB: total bilirubin; PaO<sub>2</sub>: partial pressure of oxygen; PaCO<sub>2</sub>: partial pressure of carbon dioxide; AaPO<sub>2</sub>: alveolar arterial oxygen gradient; VEGF: vascular endothelial growth factor; TNF- $\alpha$ : tumor necrosis factor  $\alpha$ ; NA: non-analysis; <sup>a</sup> P < 0.05 compared with CBDL rats with vehicle treatment; <sup>b</sup> P < 0.05 compared with sham rats with vehicle treatment; \* P < 0.05 compared with sham rats with or without rosuvastatin treatment; <sup>#</sup> P = 0.061 compared with CBDL rats with vehicle treatment.

From Chang, C.C. et al. Rosuvastatin improves hepatopulmonary syndrome through inhibition of inflammatory angiogenesis of lung. Clin. Sci (Lond). **2015**, 129, 449–460.